Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed...

MRK : 101.87 (-0.01%)
ALNY : 269.95 (-1.45%)
GILD : 89.84 (+0.37%)
GSK : 36.97 (+0.24%)
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...

JNJ : 158.24 (-1.18%)
GSK : 36.97 (+0.24%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost significantly in the past couple of years due to declining sales amid low demand for the...

MRNA : 53.54 (-2.00%)
GSK : 36.97 (+0.24%)
PFE : 27.76 (-1.17%)
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps...

AZN : 71.43 (+0.01%)
REGN : 828.84 (-1.75%)
GSK : 36.97 (+0.24%)
SNY : 52.95 (-0.60%)
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps...

AZN : 71.43 (+0.01%)
REGN : 828.84 (-1.75%)
GSK : 36.97 (+0.24%)
SNY : 52.95 (-0.60%)
2 Best Artificial Intelligence Stocks to Buy in October

These companies could have more growth ahead than investors realize.

NVDA : 136.05 (+0.48%)
AI : 24.84 (-0.76%)
GSK : 36.97 (+0.24%)
PLTR : 41.41 (-1.22%)
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention...

GILD : 89.84 (+0.37%)
GSK : 36.97 (+0.24%)
PFE : 27.76 (-1.17%)
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine,...

MRNA : 53.54 (-2.00%)
GSK : 36.97 (+0.24%)
PFE : 27.76 (-1.17%)
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.

GSK : 36.97 (+0.24%)
The Hidden Power Of Spinoffs: Why They Continue To Outperform

CVS just announced it was considering a breakup. Why is that important? Spinoffs are one of the best-kept investment secrets, despite the fact that many investors typically disregard them and frequently...

PYPL : 78.13 (+1.14%)
CVS : 54.65 (-2.08%)
MDLZ : 68.36 (-0.22%)
TRIP : 16.34 (+1.30%)
COP : 108.86 (+0.95%)
KHC : 33.38 (-0.33%)
EXPE : 161.11 (+1.07%)
HLN : 9.76 (+0.31%)
PFE : 27.76 (-1.17%)
PSX : 121.03 (+0.85%)
EBAY : 60.23 (+3.65%)
VTRS : 11.45 (-1.46%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings?
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar